LCT Appoints Scientific Advisors

Living Cell Technologies Limited

CAN: 104 028 042

ASX: LCT

OTCQX: LVCLY

ASX ANNOUNCEMENT

LCT Appoints Scientific Advisors

23 September 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited (LCT) has appointed three high-level scientific advisors to review and support its work as NTCELL progresses towards commercialisation. The appointments are Professors Anne Young from Harvard, Roger Barker from Cambridge and Richard Faull from Auckland. All are internationally recognised experts on the discovery of new treatments for neurodegenerative diseases.

Professor Anne B Young, MD PhD, Distinguished Julieanne Dorn Professor of Neurology, Harvard Medical School, Boston, United States, has over 40 years’ experience studying functional neuroanatomy. Her current research focuses on studies of new therapeutic strategies for Parkinson’s and Huntington’s diseases.

Professor Roger Barker, MD PhD FRCP, Professor of Clinical Neurosciences and Deputy Director, John van Geest Centre for Brain Repair, University of Cambridge, United Kingdom, has extensive experience in evaluating and developing new therapies for Parkinson’s and Huntington’s diseases including cell therapies. His studies focus on disease heterogeneity using cognitive testing, functional imaging and genetic biomarkers.

Professor Richard Faull, ONZM MBChB PhD DSc FRSNZ, Distinguished Professor of Anatomy and Director, Centre for Brain Research, University of Auckland School of Medicine, has over 40 years’ research experience in anatomical studies of human brain neuronal growth. He directs the Centre for Brain Research which carries out research and development programs targeting neurodegenerative diseases such as Parkinson’s, Huntington’s, motor neuron and Alzheimer’s diseases.

Dr Ken Taylor, LCT chief executive says that input from these three internationally recognised experts will certainly add huge value.

“Their oversight and expertise will enhance LCT’s ability to develop and market NTCELL® therapy for Parkinson’s patients failing current therapy. Their expertise will also prove invaluable as we investigate the potential of our patented cell therapy for other neurodegenerative disorders,” said Dr Taylor.

- Ends -

© Scoop Media